VAM
UTHR icon

Visium Asset Management’s United Therapeutics UTHR Stock Holding History

Visium Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,200
Closed -$383K – 1186
2015
Q2 		$383K Sell
2,200
-600
-21% -$108K 0.01% 728
2015
Q1 		$483K Buy
2,800
+100
+4% +$15.2K 0.01% 694
2014
Q4 		$350K Buy
+2,700
New +$348K ﹤0.01% 834
2014
Q3 		– Sell
-2,600
Closed -$230K – 1228
2014
Q2 		$230K Buy
+2,600
New +$250K ﹤0.01% 954
2013
Q4 		– Sell
-3,650
Closed -$288K – 984
2013
Q3 		$288K Sell
3,650
-311
-8% -$22.7K 0.01% 644
2013
Q2 		$261K Buy
+3,961
New +$255K 0.01% 599

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Visium Asset Management's UTHR Position: Q3 2015 in Review

Visium Asset Management sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 2,200 shares — an estimated $383K sold.

Visium Asset Management first reported a position in UTHR in Q2 2013 and held it in 6 quarters. The position peaked at $483K in Q1 2015. 372 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

  • Visium Asset Management reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 2,200 United Therapeutics shares in Q3 2015, an estimated $383K.
  • Visium Asset Management first reported a position in United Therapeutics in Q2 2013 and held it in 6 quarters.
  • Visium Asset Management's United Therapeutics position peaked at $483K in Q1 2015.
  • 372 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.